← All trials
NCT05929807
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 21, 2023
- Primary completion
- Jan 31, 2039
- Completion date
- Mar 31, 2039
- First posted
- Jul 3, 2023
- Last posted
- Dec 29, 2023
- Enrollment
- 140
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ascendis Pharma, Inc.Lead sponsor
- Ascendis Pharma, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.